Total Funding
6
Total FundingSeries B raised
Growth Score
pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
ALDEA Pharmaceuticals develops small-molecule modulators of the ALDH family for the treatment of toxic aldehyde-related diseases.
John Walker: DirectorPast Role: Rhithm, Chief Operating Officer
Asha Rajagopal: Acting Chief Financial OfficerPast Role: BEFORE Brands, VP Finance
About the Company
ALDEA Pharmaceuticals is developing small-molecule modulators of the aldehyde dehydrogenase enzyme (ALDH) family, to treat toxic aldehyde-related diseases. This proprietary technology represents new product opportunities to address novel targets across multiple therapeutic areas. For example, an ALDH activator compound enhances the detoxification
of acetaldehyde in the alcohol metabolism pathway, to treat acute symptoms and to reduce long-term tissue damage and cancer risk.
The company was founded in 2011 and headquartered in Redwood City, California.
Women Founded
